Company Profile

In accordance with Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018, for the Quarter ended on March 31, 2024, based on the certificate received from Beetal Financial & Computer Services (RTA) dated 05/04/2024, which is enclosed, Titan Biotech has forwarded the same.

The above information is a part of company’s filings submitted to BSE.

Rail Vikas Nigam has been emerged as the Lowest Bidder (L1) from Madhya Pradesh Paschim Kshetra Vidyut Vitran Company for ‘Supply, Installation, Testing and Commissioning of New 11 KV line for Bifurcation & Interconnection, Additional 11 KV Bay at 33 / 11 KV Substation, Augmentation of conductor of 33 KV & 11 KV Lines, Additional Distribution Transformer Substations with associate New 11 KV Lines, LT Line on AB cable, Conversion of bare LT line with AB Cable, Augmentation of LT AB Cable, Cover conductor for 11 KV Line Crossing Agriculture & Non Agriculture Feeder, 11 kv and 33 kv Bus Bar renovation other associated work and Supporting works such as DPs, TPs, Crossing etc. in Jhabua O&M Division (LOT-12) under the Revamped Reforms-based and Results-linked, Distribution Sector Scheme'. The project cost is Rs 106.37 crore. The order is expected to be executed within 24 months.

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Deflazacort Tablets, 6 mg, 18 mg, 30 mg and 36 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), EMFLAZA tablets 6 mg, 18 mg, 30 mg and 36 mg of PTC Therapeutics Inc. The product will be launched in February 2024.

Life Insurance Corporation of India (LIC) has increased its shareholding in ‘SBI Cards & Payments Services’. The company has increased its shareholding from 47,410,710 to 47,711,794 equity shares, i.e., 4.99% to 5.02% of the paid-up capital of the said company.     

Lemon Tree Hotels has signed a License Agreement for upcoming hotel in Marpalle, Vikarabad District, Telangana under the Company’s brand ‘- Lemon Tree Resor’. This hotel will be spread over 5 acres and have 50 rooms including 14 villas of which 5 would be water villas. The resort would feature a restaurant, a bar, a banquet hall, meeting rooms, a swimming pool, a fitness center, and other public areas. It will have large lawns to cater to destination weddings and is expected to be operational in FY27. Carnation Hotels, a wholly-owned subsidiary and the hotel management arm of the Company will be operating this Hotel. 

Zee Media Corporation has received approval for incorporation / establishing of a wholly owned subsidiary of the Company with such name as may be approved by the Registrar of Companies, Ministry of Corporate Affairs. 

Titan Biotech is all set to acquire 33,90,510 partly paid up equity shares of Rs 24 each at par aggregating to Rs 8.13 crore out of which Rs 2.03 crore will be paid on application (only application) by way of subscribing to the rights issue of Titan Media (Investee Company). In this regard, the Company is all set to acquire equity shares equivalent to voting rights of 64.58% of the total issued and paid up share capital of the Investee Company whenever the Investee Company will make a further calls on the said issue.

Reserve Bank of India (RBI) Governor Shaktikanta Das firmly dismissed any possibility of a review of the central bank’s action against One 97 Communications' Paytm Payments Bank. He stated that the decision was taken after a comprehensive assessment of the firm’s operations.

Titan Bio-Tech is currently trading at Rs. 520.00, up by 56.40 points or 12.17% from its previous closing of Rs. 463.60 on the BSE.

The scrip opened at Rs. 523.90 and has touched a high and low of Rs. 529.80 and Rs. 511.60 respectively. So far 4251 shares were traded on the counter.

The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 550.00 on 10-Jan-2024 and a 52 week low of Rs. 193.10 on 29-Mar-2023.

Last one week high and low of the scrip stood at Rs. 536.90 and Rs. 451.10 respectively. The current market cap of the company is Rs. 383.11 crore.

The promoters holding in the company stood at 55.88%, while Non-Institutions held 44.12% stake in the company.

Titan Biotech is all set to acquire 33,90,510 partly paid up equity shares of Rs 24 each at par aggregating to Rs 8.13 crore out of which Rs 2.03 crore will be paid on application (only application) by way of subscribing to the rights issue of Titan Media (Investee Company).

In this regard, the Company is all set to acquire equity shares equivalent to voting rights of 64.58% of the total issued and paid up share capital of the Investee Company whenever the Investee Company will make a further calls on the said issue.

The company stake in Investee Company will increase in proportionally on each call. Currently, the Company will pay the 25% on application (Tranches 1) amount and rest will be paid on further calls of the said issue.

Titan Biotech is one of the leading manufacturers & exporters of the biological products used in the field of Pharmaceutical, Nutraceutical, Food & Beverages, Biotechnology & Fermentation etc.

Titan Biotech is all set to acquire 33,90,510 partly paid up equity shares of Rs 24 each at par aggregating to Rs 8.13 crore out of which Rs 2.03 crore will be paid on application (only application) by way of subscribing to the rights issue of Titan Media (Investee Company).

In this regard, the Company is all set to acquire equity shares equivalent to voting rights of 64.58% of the total issued and paid up share capital of the Investee Company whenever the Investee Company will make a further calls on the said issue.

The company stake in Investee Company will increase in proportionally on each call. Currently, the Company will pay the 25% on application (Tranches 1) amount and rest will be paid on further calls of the said issue.

Titan Biotech is one of the leading manufacturers & exporters of the biological products used in the field of Pharmaceutical, Nutraceutical, Food & Beverages, Biotechnology & Fermentation etc.